Elsevier, a global provider of information and analytics, has added approximately 500,000 records from ClinicalTrials.gov to Embase, its biomedical literature database. This integration enables researchers to access clinical research studies and their outcomes alongside peer-reviewed publications, in-press articles, and conference abstracts within a single platform.
The newly added content, covering studies conducted in over 200 countries, is intended to support a wide range of research and regulatory functions, including systematic reviews, drug safety monitoring, clinical trial design, and medical device approval processes. By incorporating data from ClinicalTrials.gov, Embase now offers a more unified approach to evidence gathering, aiming to reduce errors and inefficiencies associated with searching across multiple sources.
Researchers conducting pharmaceutical and medical device research often require comprehensive data retrieval across diverse platforms to meet regulatory demands and support internal decision-making. Fragmentation across databases can delay workflows due to duplicated results and inconsistent indexing. By consolidating published literature and clinical trial records in Embase, Elsevier seeks to streamline search processes and improve information alignment.
The integrated trial data will be indexed using the latest Emtree terminology. Records will include titles, brief summaries, and detailed descriptions, enhancing discoverability within Embase’s existing interface. This development supports various Embase use cases, including medical affairs analysis, safety monitoring, competitive intelligence, and evidence generation for market approval.
An additional update is scheduled for late 2025, when Embase will expand its ClinicalTrials.gov coverage to include eligibility criteria and study protocol information. This enhancement will further consolidate Embase’s role as a comprehensive resource for both published biomedical research and clinical trial registry data.
According to Elsevier, this update responds to sustained customer demand for integrated trial data. The organization stated that the expanded access will help researchers reduce manual search time while maintaining accuracy and completeness in their evidence evaluations.
Click here to read the original press release.
